Is Chimeric Therapeutics Ltd halal to invest in?

As of July 2026, Chimeric Therapeutics Ltd CHM.AX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Chimeric Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Chimeric Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Chimeric Therapeutics Ltd?

Muslim investors may consider investing in Chimeric Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Chimeric Therapeutics Ltd classified as HALAL?

Musaffa determines the Shariah status of Chimeric Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Chimeric Therapeutics Ltd updated?

The Shariah compliance status of Chimeric Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Chimeric Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Chimeric Therapeutics Ltd?

You can check the latest Shariah compliance status of Chimeric Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Chimeric Therapeutics Ltd CHM.AX

Last Updated: Jul 21, 12:00 AM·ASX

CHM.AX Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Chimeric Therapeutics Ltd is classified as halal.

HALAL

Report Source: 2025 2nd Quarter Report

Chimeric Therapeutics Ltd. Stock Analysis CHM.AX

Australia Health Care Nano Cap Report: Q2, 2025

Chimeric Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. The company is also building a Cell therapy portfolio.

Key Statistics of Chimeric Therapeutics Ltd (CHM.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.04AUD0.05

Today's Open

AUD0.04

Volume

136.86K

P/E Ratio (TTM)

52 Week Range

AUD0.04AUD0.60

Market Cap

3.11M

Avg. Volume

4.90M

Dividend Yield

Financial Metrics & Statements of Chimeric Therapeutics Ltd (CHM.AX)

Super Investors Invested in Chimeric Therapeutics Ltd (CHM.AX)

FAQ's for Chimeric Therapeutics Ltd (CHM.AX)

As of July 2026, Chimeric Therapeutics Ltd CHM.AX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Chimeric Therapeutics Ltd using these criteria to determine its compliance status.
Muslim investors may consider investing in Chimeric Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Chimeric Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Chimeric Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Chimeric Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.